CA1052271A - 1,2 - and 2,3 - epoxy alkanes - Google Patents
1,2 - and 2,3 - epoxy alkanesInfo
- Publication number
- CA1052271A CA1052271A CA221,651A CA221651A CA1052271A CA 1052271 A CA1052271 A CA 1052271A CA 221651 A CA221651 A CA 221651A CA 1052271 A CA1052271 A CA 1052271A
- Authority
- CA
- Canada
- Prior art keywords
- composition
- formula
- epoxy
- carbon atoms
- epoxy alkanes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000004593 Epoxy Substances 0.000 title abstract description 16
- 150000001335 aliphatic alkanes Chemical class 0.000 title abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 210000002307 prostate Anatomy 0.000 claims abstract description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 12
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract description 9
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 9
- 230000003248 secreting effect Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 206010036940 Prostatic adenoma Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 238000000034 method Methods 0.000 description 16
- 210000000981 epithelium Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 10
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 7
- VHMBMZSDFOQAHR-HWKANZROSA-N (e)-icos-2-ene Chemical compound CCCCCCCCCCCCCCCCC\C=C\C VHMBMZSDFOQAHR-HWKANZROSA-N 0.000 description 6
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 150000004965 peroxy acids Chemical class 0.000 description 5
- VGYBKPBFRIXAST-UHFFFAOYSA-N 2-heptadecyl-3-methyloxirane Chemical compound CCCCCCCCCCCCCCCCCC1OC1C VGYBKPBFRIXAST-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940073584 methylene chloride Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- INJRDZMWIAYEMM-UHFFFAOYSA-N 9-Oxo-2-decenoic acid Natural products CC(=O)CCCCCC=CC(O)=O INJRDZMWIAYEMM-UHFFFAOYSA-N 0.000 description 2
- INJRDZMWIAYEMM-SOFGYWHQSA-N 9-Oxo-2E-decenoic acid Chemical compound CC(=O)CCCCC\C=C\C(O)=O INJRDZMWIAYEMM-SOFGYWHQSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- -1 chloromethylene Chemical group 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- RHEVFAMQJMWLFS-UHFFFAOYSA-N icosan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCC(C)O RHEVFAMQJMWLFS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- GLVYLTSKTCWWJR-UHFFFAOYSA-N 2-carbonoperoxoylbenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1C(O)=O GLVYLTSKTCWWJR-UHFFFAOYSA-N 0.000 description 1
- HFOFYNMWYRXIBP-MOPGFXCFSA-N 2-methyl-7S,8R-Epoxy-octadecane Chemical compound CCCCCCCCCC[C@H]1O[C@H]1CCCCC(C)C HFOFYNMWYRXIBP-MOPGFXCFSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- YTKRILODNOEEPX-NSCUHMNNSA-N crotyl chloride Chemical compound C\C=C\CCl YTKRILODNOEEPX-NSCUHMNNSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 150000002901 organomagnesium compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A B S T R A C T
The invention relates to novel compounds in the form of epoxy alkanes corresponding to the formula (I) in which B is H or CH3 and A represents a hydrocarbon radical containing at least 15 carbon atoms.
These epoxy alkanes are suitable for therapeutic application, especially in the treatment of secretory disorders of the prostate gland, more especially prostate adenoma.
The invention relates to novel compounds in the form of epoxy alkanes corresponding to the formula (I) in which B is H or CH3 and A represents a hydrocarbon radical containing at least 15 carbon atoms.
These epoxy alkanes are suitable for therapeutic application, especially in the treatment of secretory disorders of the prostate gland, more especially prostate adenoma.
Description
lOS'~Z71 This invention relates to novel epoxides corre-sponding to formula I below. These compounds are suitable for therapeutic application, especially in the treatment of secretory disorders of the prostate gland and more especially in the treatment of prostate adenoma.
In Patent Application No. 40568/73 filed 29th August, 1973, it was shown that higher alkanols with 16 or more carbon atoms are suitable for therapeutic application in the treatment of secretory disorders of the prostate gland, especially prostate adenoma. It has now been found that 1,2-and 2,3-epoxy alkanes corresponding to the general formula:
\0/ : ' in which B is H or CH3 and A is a hydrocarbon radlcal contain-ing at least 15 carbon atoms, :
and their geometric isomers are as active as the above-mentioned alkanols.
In order to complete acknowledgement of the prior art, it is pointed out that, although the 1,2- and 2,3-epoxy alkanes of formula I are new and show interesting therapeutic properties, only a single Cl9 epoxy alkane is already known.
The compound in question, namely cis-7,8-epoxy-2-methyl-octadecane, is a queen substance found in lepidoptera. It is emitted by females of Port~etria di~par to attract males with : the object of intraspecific copulation. This queen substance is a laboratory curiosity. After extraction, its structure was established by BEROZA in Journal of Association of Officinal Analytical Chemists (1971), 54, 251, and then con-firmed by synthesis by EITER in Angew. Chem. Internat.
(English Edition), (1972), 11, 60.
~ 30 In accordance with the definition of formula I, the ", 1 ~
,~ .
~05~271 invention relates to l,2-epoxy alkanes with 18 or more carbon atoms and their geometric isomers, and 2,3-epoxy alkanes with 19 or more carbon atoms and their geometric isomers.
In the context of the invention, the "hydrocarbon radical" A is a straight-chain or branched-chain hydrocarbon radical with at most 15 carbon atoms. As illustrated herein-after, the preferred hydrocarbon radicals are those with a linear chain, in which case A represents in particular ( 2)15' (CH2)16~ (CH2)17~ (CH2)l8~ (CH2)19 and (CH2)20. The lower limit of 15 carbon atoms was determined by a statistical activity study, as will be seen hereinafter.
The compounds of formula I are prepared in known manner by reacting a corresponding alkene with a peracid. The method used comprises reacting 1 mol of an alkene correspond-ing to the formula:
CH3-A-CH=CH-B (II) in which A and B are as defined above, with more than 1 mol of peracid at ambient temperature (15-25C).
Peracids which may be used for this purpose include, in particular, peracetic acid, perbenzoic acid, perphthalic acid and metachloroperbenzoic acid. Although these peracids are equivalent, it has been found that the use of metachloro-perbenzoic acid is more economic from the commercial point of view, especially in regard to the purity of the end product.
The reason why it is more economic to use metachloroperbenzoic acid is that the metachlorobenzoic acid formed during the reaction is easier to remove than the other acids.
In order to carry out this reaction, 1.1 mol of metachloroperbenzoic acid is reacted with 1 mol of alkene II
in an inert solvent, such as methylene chloride.
~OSZZ7~L
The l-alkenes of formula II are commercially availa-ble products. The 2-alkenes of formula II may be prepared in particular a) from the corresponding 2-alkanols by treatment with H2S04 or b) by reacting an organomagnesium compound of formula III with l-chloro-2-butene (formula IV) in accordance with the following scheme:
Br-Mg-A'-CH3 + Cl-CH2-CH=CH-CH3 >
(III) (IV) CH3-CH-CH-CH2-A'-CH3 where A' is a hydrocarbon radical containing at least 14 carbon atoms.
Methods A and B described below each represent one method of preparing 2,3-epoxy eicosane from 2-eicosene by oxidation with metachloroperbenzoic acid (Method A) and with peracetic acid (Method B). Methods C and D relate to the preparation of a starting alkene, namely 2 eicosene.
Method A
6 g of 2-eicosene are dissolved in 100 cc of methyl-ene chloride and the resulting solution is introduced into a flask equipped with a condenser and a stirrer (if necessary, this flask may be immersed in a cooling or heating bath).
; 4 9 of metachloroperbenzoic acid, i.e. a molar excess of approximately 10% relative to the stoichiometric quantity, are progressively introduced (over a period of ; approximately 30 minutes). The mixture is stirred and kept at ambient temperature (15-25C) during the addition by means of a stream of water, and is then left standing at ambient temperature for about 10 hours. The mixture is then heated under reflux for 2 hours in order to destroy the peracid.
A large quantity of the metachlorobenzoic acid formed precipitates after cooling. It is eliminated by 1(:)5Z;~7~L
filtration. The chloromethylene solution is washed first with 100 cc of sodium sulphite (100 g/l) and then with 100 cc of sodium bicarbonate (100 9/1) and finally with water until it has a pH-value above 6. The organic solution is dried over calcium chloride and then distilled to remove the methylene chloride. 4.8 9 of product are obtained, corresponding to a crude yield of 76%.
The product is purified by column chromatography.
100 9 of chromatography-grade silica suspended in petroleum ether are introduced into a 3.5 cm diameter glass column. After the gel has been introduced, the crude product obtained is introduced at the head of the column after having been dissolved in a minimal volume of petroleum ether. The column is then washed with petroleum ether, which enables 0.2 9 of product to be removed to be recovered in 1 litre of washing solvent. Elution is then carried out with a 90 : 10 mixture of petroleum ether and diethylether. 4.5 9 of 2,3-epoxy eicosane are recovered from 500 ml of the eluate. Mp:
40C, bp 15mm Hg : 200-210C.
Method B
7 9 of 2-eicosene are dissolved in 20 g of peracetic acid. The ethylenic function is oxidized into epoxide in the absence of heat. The acetic acid formed is neutralized in 10 ml of water by the addition of lN NaOH. The aqueous solution thus obtained is extracted with ether. Removal of the ether leaves 6 9 of 2,3-epoxy eicosane which is purified in the same way as described above. Mp: 40C, bp 15mm Hg : 200-210C. -~
Method C
35 9 of a 60% by weight solution of sulphuric acid are introduced into a 100 ml flask equipped with a condenser and stirrer and heated in an oil bath. 7 9 of 2-eicosanol .. . .
.... . . , . . :
- . . :
. ~ .
lOS;~Z71 (0.0234 mol) are introduced into the flask, followed by heating under reflux (100-110C) for 16 hours.
After cooling, the reaction product is extracted with 200 ml of chloroform, the chloroformic solution washed twice with 150 ml of sodium carbonate (100 9/l) and then several times with water until a pH value above 6 is obtained.
The chloroformic solution is dried over calcium chloride, the chloroform is removed by distillation and, finally, the residue is distilled at around 180C/15 mm Hg. 6 9 of 2-eicosene are obtained, corresponding to a yield of 85%.
Method D
61 9 of l-bromohexadecane are dissolved in 100 ml of dry ether. 4.86 9 of magnesium turnings are then introduced into the flask. These quantities are stoichiometric.
The Grignard reaction is initiated in the usual way by adding an iodine crystal. Once started, it is externally controlled by means of an ice bath and held under reflux. It stops spontaneously after a few minutes.
On completion of the operation, a solution contain-ing 18 9 of 1-chloro-2-butene in 20 ml of dry ether is added in the absence of heat. The exothermic reaction is held under natural reflux which stops after about 15 minutes.
The cooled solution is washed with water containing ; an excess of hydrochloric acid in order to dissolve the magnesia formed. The ethereal solution is recovered by decan-tation and then dried. The ethylenic compound, namely 2-eicosene, is obtained in a quantitative yield. It is purified by distillation in va~uo at 160C/l mm Hg.
After the heads and tails have been removed, 7 9 of product are obtained, its composition and purity being readily verified by N.M.R.
i-.. ~,, , - , . , - ........................ - ......... .
- ~ .
lOS;~Z7~
A few epoxy alkanes corresponding to formula I and two comparison products, A-l and A-2, are shown in Table I
below, all these products having been prepared by Method A.
The 2,3-epoxy eicosane prepared by methods A and B is also shown in this table (Example 4).
It is recommended to use therapeutic compositions containing, in association with a physiologically acceptable excipient, a therapeutically effective quantity of at least one compound corresponding to formula I.
Any physiologically acceptabie liquid or solid vehi-cles may be used for preparing these therapeutic compositions containing the higher epoxy alkanes according to the invention.
; Solid preparations include, in particular, powders, tablets, granules, capsules, dragees and suppositories.
The solid vehicle which may be used contains one or more substances acting as diluent, perfume, solubilizer, lubricant, binder, surfactant or disintegration agent in the case of tablets. The solid vehicle may also contain one or more encapsulating substances. In powder form, the active compound is associated with a finely divided solid vehicle.
In tablets, the active compound is mixed in suitable pro-portions with a vehicle having the requisite binding proper-ties. The powders and tablets contain from 1 to 90% by weight of active ingredient. Suitable solid vehicles are, in par-ticular, magnesium carbonate, magnesium stearate, talcum saccharose, glucose, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxy methyl cellulose, -; low-melting waxes and cocoa butter.
,, .
Liquid preparations include solutions, suspensions and emulsions. In this case, the vehicle may be an aqueous solution of polyethylene glycol or polypropylene glycol on the .
: .
,, ,. . ~
i ~
lOS;~Z7~
one hand and oil, especially olive oil on the other hand.
The aqueous suspensions for oral administration are prepared by dispersing the finely divided active compound in water with a viscous substance, a natural or synthetic gum, a resin, etc., for example with gum arabic, an ion-exchange resin, methyl cellulose, carboxy methyl cellulose or any other well known suspending agent. The results of pharmacological tests carried out with the compounds according to the in-vention are summarized in the following.
The histological changes produced in the epithelium of adult rats were examined. It was found that the compounds according to the invention were capable of stimulating the function of the prostate gland in adult rats orally treated with very small doses over periods ranging from 15 days to 3 months. A significant improvement was then observed, for example with a dose of 0.5 mg per Kg of body weight per day in the case of the products of Examples 1 to 6.
Technique The epoxy alkane to be tested in an excipient, for example olive oil, was administered daily in the dose indi-cated for the period indicated to adult rats aged approxi-mately 9 months.
Control rats are only given the excipient.
in the test described, the animals were treated 6 days a week for 7 weeks. Each epoxy alkane was administered in solution in a volume of 0.1 ml/100 9 of body weight, i.e.
in a concentration of 0.5 9 of product per litre of oil.
- On completion of the test, the control animals and treated animals were killed, the ventral part of their - 30 prostate glands removed, fixed with alcohol and then histolog-ically examined.
lOS;~Z71 ~
The state of sections cut from the periphery of the prostate glands is noted in accordance with the following ~;
schedule:
Epithelium + 1 Enlargement of the peripheral epithelium of the central glands assuming a cubic appearance and occupying more than the outer half of the surface of the prostate gland.
Epithelium + 2 Enlargement of the epithelium, assuming a cylindri-cal appearance throughout.
Epithelium + 3 Epithelium identical throughout with that of theperipheral glands.
Epithelium + 4 Papillary hyperplasia of the epithelium with hyper-secretion (this "stage" was not observed in the tests con-ducted).
Table II below shows the results relating to the ventral prostates examined after killing of the controls and treated animals which had been given the epoxy alkanes of Examples 1 to 6 and comparison examples A-l and A-2 in the doses indicated.
Table II also shows the results of a statistical study carried out by the "chi 2" (x2) and the EPP index method.
The "chi 2" method enables the probability factor "p" to be deduced. The EPP index (examination of the periphery of the prostate gland) is defined as the ratio of the sum of all the -~
animals classed "epithelium 11'' bearing the coefficient 1, "epithelium 2+" bearing the coefficient 2 and "epithelium 3+"
bearing the coefficient 3 by the number of animals,...........
enables the statistical study to be confirmed. As indicated 105~271 in Table II, there is no activity when EPP is less than 1.80, whereas activity is found at the level of the prostate gland where EPP is greater than or equal to 1.80.
In conclusion, examination of the ventral part cut out from the periphery of the prostate glands shows that comparison products A-l and A-2, which respectively contain a Cg and C13 hydrocarbon radical, are inactive because they give a result similar to the control group. This absence of activity in products A-l and A-2 is confirmed by the statisti-cal study in relation to the controls in accordance with the "chi 2" method. In addition, in the series of epoxy alkanes corresponding to formula I, the activity of the level of the prostate glands begins to appear when the hydrocarbon radical -A contains at least 15 carbon atoms, as is the case with the compound of Example 1, in whose case a significant difference is noted in relation to the controls. The compounds of Examples 2 to 6 are highly active.
. .
It is apparent from the foregoing that the 1,2-epoxy alkanes of formula I are active when they contain in their molecule at least 18 carbon atoms, and that the 2,3-epoxy alkanes of formula I are active when they contain at least 19 carbon atoms ;n their molecule.
:. - g ' ' ~05~271 ,, ~ ~
O I O ~ O~ ~ O O U~ O
C~_ N 1~ ~ O ~ N
E ,_ ~ ~ . N N N N N
E o ~ o oo ~ ~ o m O L~ O
._ ~ ~~ I~ a~ o o o o ~- ~ ~ ~ ~ N N N N N
O ~
~ ~S
~ N 1~1 :
._ aJ ._ ._ O ~ ~
C~_ ~ :~ . r l~ O
~:n ~ ~ ,~ ~ ~ I
C-- O ~ ~ _ U~ ~, o) >, N (~0 O 00 N
~> ~ 3 3 r-- O ~ E ~.) O (_~ O
~ -- E
S ~ ~5 ~ ' ~ ' V~
O
o u~ I
._ V) ~5 ~r) N C~J O ~D O ~D N
1~ ~_ ~ ~ Ll~
cl r- ~ ~ <r~
,_ 18 >
~ ~00 ~ U~ l O
E
~_~ oI~ ~ o o ~ ,~
~ q_ 1~ 1-- 00 oo oo CO CO o~
L~ ~ ~
CS ~
I_ tl:l 01 ~ N ~ ~ _ ~ d' ~ C~
~ 0~ ~ O _ _ _ C~
N 1~ N 1~ N
~15 ~ 8 O d O O O 00 0 ~ O ~ O~O O d- O N
_ _ ~ CO N '~t ~~0 O 0~ d' N O a~ d' N 00 1 C ~ N _ ~ N ~) N ~t N d- t~) d- N
~- E
_ N ~ 00 0 N O N
E o _ _ _ N N N N N , I I I '-~ .- ~ ~ ~ ~
a) N tlS N ~ N a,l ~ 1) 1 U) N C- I ~.. ) I O I C ~ I O
1 0~ 1 0~ 1 0 V) I O U~ l O ~ l O ~ l O ~
I O ~~ I/ O I/ OI/ O I~ O I/ _ a~ I/ ~ ~ X C~ ~ t~ ) ~ U~_) ~) t_) Q 1~ ~ O I al I ~ I --I O I _I O I
o _ ~ o 1~ ~ o~ ~ ~ a) oo ~1 o _ ~ O~ I _ I _ I _ I _ I _ I _ I N
> C N X N X N X N X N X N X N X N X
~I) O I O I O I O I O I O I O I O I O
C~ 1~ C_) Q~.) Qt_~ Q C_~ QC_~ Q ~_) Q ~.7 Q ~_) Q
~r) N ~ N ~ N (~ N~) N~r I ^ I ^ I ^ I ^ I ^ I ^ I ^ I
r~ ~ ~ N C~ N ~ N
O
. Z ,_ Q _ N O N
E aJ , , N N N
0 ~1 ~ C~ _ N ~) ~ I L~) I ~ I
X O
- ' . . ,,:, ' ' -^ ^ ~VS;~Z'7~
V ~, _ ~ ~
o C ~ ~, cn o o o o ~) ~, ~ ~ c~ >, c ., ., _ ~
~ ~ c~ C c~-, a~ aJ a~ a~ aJ
E a~ s ~ > ~ ~ ~ ~ ~
a~ ~ Q ~ Q. ,-, , , , , ~ ^
o Eo E ~ ~ ~ ~ ~ ~ +
~ o~s o a cr ~cr ~ a tu ~ ~ ~ ~
E
., L~ U~ 1~ O O LO In O O
. ~ ~ ~ ~ c~ ~ o cn cs~
. c~ v . _~ ~ ~ N ~ ~ C~l ~ a~
L~ Q .
~ a~ E
o ~ x ~ ~ ~ ~ ~ ~ x ~
~ .-- ~ c-- ~ c~ c~ c-- c-- o 3 ~ ~ ~ a~ a~ ~ ~ a) . a~
~_ ~ --- ~ 3 u~ c~l 3 c~J ~ 3 ~ o 3 ~ o 3 ~ o ~ ~
~ v~ vl v~ ~ O O ~ O O ~ O O~ O O ~ O O O ^ E
o, a~ a~ ~ ~ ~ cJ ~ t ., ~ _ ~ C-- ~ O O ~ O O ~ O O~ O O1:~ 0 0 a5 N
E
c- I~ I~ u~ r~ ~ c~J ~ ~ ~5 ~
~ o o ~ I~ oo ~ m ~ o~ , O
E o N CO cn C~ N cn ,- _ o ~ . . . . . . . a~ ~
O N r~ 00 N C~J ~) 1~) C--aJ
_ _ +~ ~
+ S:L ~
a~ ~>
, +
n ILI
E
+ ~ t-c~ ~ .~>
E s 4-., , ., ~_ _ n cr a)oo1~1~ o oo ~ _ o o a~ ., ~ _ _ _ _ ~ ~
~ x c~ Q O
L~J _ ll ll ., +
., _ ~ In E
, ~ c~
c_c~l _ _, +~
.j , ~ .
'I CL
:` ~ .~ .
~ ~, ~
,, o ~s .) _ . ~ c--a~ 8 o o a~ o o o o o o v~ ~
E ~ N _ N N C`J C~
E-, - ~ ~
z ~ ~) v . Q ~ ~
.' .~ ~
_ +~
.
O _. ~ ^
Z ~- OC~l ~ V) V
O. - N C`J C~l N
a~ _ I I , , , .. ..
O ~ ~ ~ l C~
_ O C_ ~ ~ O ~+ 1~)~ `_ ~
~ _ 11 _ ,
In Patent Application No. 40568/73 filed 29th August, 1973, it was shown that higher alkanols with 16 or more carbon atoms are suitable for therapeutic application in the treatment of secretory disorders of the prostate gland, especially prostate adenoma. It has now been found that 1,2-and 2,3-epoxy alkanes corresponding to the general formula:
\0/ : ' in which B is H or CH3 and A is a hydrocarbon radlcal contain-ing at least 15 carbon atoms, :
and their geometric isomers are as active as the above-mentioned alkanols.
In order to complete acknowledgement of the prior art, it is pointed out that, although the 1,2- and 2,3-epoxy alkanes of formula I are new and show interesting therapeutic properties, only a single Cl9 epoxy alkane is already known.
The compound in question, namely cis-7,8-epoxy-2-methyl-octadecane, is a queen substance found in lepidoptera. It is emitted by females of Port~etria di~par to attract males with : the object of intraspecific copulation. This queen substance is a laboratory curiosity. After extraction, its structure was established by BEROZA in Journal of Association of Officinal Analytical Chemists (1971), 54, 251, and then con-firmed by synthesis by EITER in Angew. Chem. Internat.
(English Edition), (1972), 11, 60.
~ 30 In accordance with the definition of formula I, the ", 1 ~
,~ .
~05~271 invention relates to l,2-epoxy alkanes with 18 or more carbon atoms and their geometric isomers, and 2,3-epoxy alkanes with 19 or more carbon atoms and their geometric isomers.
In the context of the invention, the "hydrocarbon radical" A is a straight-chain or branched-chain hydrocarbon radical with at most 15 carbon atoms. As illustrated herein-after, the preferred hydrocarbon radicals are those with a linear chain, in which case A represents in particular ( 2)15' (CH2)16~ (CH2)17~ (CH2)l8~ (CH2)19 and (CH2)20. The lower limit of 15 carbon atoms was determined by a statistical activity study, as will be seen hereinafter.
The compounds of formula I are prepared in known manner by reacting a corresponding alkene with a peracid. The method used comprises reacting 1 mol of an alkene correspond-ing to the formula:
CH3-A-CH=CH-B (II) in which A and B are as defined above, with more than 1 mol of peracid at ambient temperature (15-25C).
Peracids which may be used for this purpose include, in particular, peracetic acid, perbenzoic acid, perphthalic acid and metachloroperbenzoic acid. Although these peracids are equivalent, it has been found that the use of metachloro-perbenzoic acid is more economic from the commercial point of view, especially in regard to the purity of the end product.
The reason why it is more economic to use metachloroperbenzoic acid is that the metachlorobenzoic acid formed during the reaction is easier to remove than the other acids.
In order to carry out this reaction, 1.1 mol of metachloroperbenzoic acid is reacted with 1 mol of alkene II
in an inert solvent, such as methylene chloride.
~OSZZ7~L
The l-alkenes of formula II are commercially availa-ble products. The 2-alkenes of formula II may be prepared in particular a) from the corresponding 2-alkanols by treatment with H2S04 or b) by reacting an organomagnesium compound of formula III with l-chloro-2-butene (formula IV) in accordance with the following scheme:
Br-Mg-A'-CH3 + Cl-CH2-CH=CH-CH3 >
(III) (IV) CH3-CH-CH-CH2-A'-CH3 where A' is a hydrocarbon radical containing at least 14 carbon atoms.
Methods A and B described below each represent one method of preparing 2,3-epoxy eicosane from 2-eicosene by oxidation with metachloroperbenzoic acid (Method A) and with peracetic acid (Method B). Methods C and D relate to the preparation of a starting alkene, namely 2 eicosene.
Method A
6 g of 2-eicosene are dissolved in 100 cc of methyl-ene chloride and the resulting solution is introduced into a flask equipped with a condenser and a stirrer (if necessary, this flask may be immersed in a cooling or heating bath).
; 4 9 of metachloroperbenzoic acid, i.e. a molar excess of approximately 10% relative to the stoichiometric quantity, are progressively introduced (over a period of ; approximately 30 minutes). The mixture is stirred and kept at ambient temperature (15-25C) during the addition by means of a stream of water, and is then left standing at ambient temperature for about 10 hours. The mixture is then heated under reflux for 2 hours in order to destroy the peracid.
A large quantity of the metachlorobenzoic acid formed precipitates after cooling. It is eliminated by 1(:)5Z;~7~L
filtration. The chloromethylene solution is washed first with 100 cc of sodium sulphite (100 g/l) and then with 100 cc of sodium bicarbonate (100 9/1) and finally with water until it has a pH-value above 6. The organic solution is dried over calcium chloride and then distilled to remove the methylene chloride. 4.8 9 of product are obtained, corresponding to a crude yield of 76%.
The product is purified by column chromatography.
100 9 of chromatography-grade silica suspended in petroleum ether are introduced into a 3.5 cm diameter glass column. After the gel has been introduced, the crude product obtained is introduced at the head of the column after having been dissolved in a minimal volume of petroleum ether. The column is then washed with petroleum ether, which enables 0.2 9 of product to be removed to be recovered in 1 litre of washing solvent. Elution is then carried out with a 90 : 10 mixture of petroleum ether and diethylether. 4.5 9 of 2,3-epoxy eicosane are recovered from 500 ml of the eluate. Mp:
40C, bp 15mm Hg : 200-210C.
Method B
7 9 of 2-eicosene are dissolved in 20 g of peracetic acid. The ethylenic function is oxidized into epoxide in the absence of heat. The acetic acid formed is neutralized in 10 ml of water by the addition of lN NaOH. The aqueous solution thus obtained is extracted with ether. Removal of the ether leaves 6 9 of 2,3-epoxy eicosane which is purified in the same way as described above. Mp: 40C, bp 15mm Hg : 200-210C. -~
Method C
35 9 of a 60% by weight solution of sulphuric acid are introduced into a 100 ml flask equipped with a condenser and stirrer and heated in an oil bath. 7 9 of 2-eicosanol .. . .
.... . . , . . :
- . . :
. ~ .
lOS;~Z71 (0.0234 mol) are introduced into the flask, followed by heating under reflux (100-110C) for 16 hours.
After cooling, the reaction product is extracted with 200 ml of chloroform, the chloroformic solution washed twice with 150 ml of sodium carbonate (100 9/l) and then several times with water until a pH value above 6 is obtained.
The chloroformic solution is dried over calcium chloride, the chloroform is removed by distillation and, finally, the residue is distilled at around 180C/15 mm Hg. 6 9 of 2-eicosene are obtained, corresponding to a yield of 85%.
Method D
61 9 of l-bromohexadecane are dissolved in 100 ml of dry ether. 4.86 9 of magnesium turnings are then introduced into the flask. These quantities are stoichiometric.
The Grignard reaction is initiated in the usual way by adding an iodine crystal. Once started, it is externally controlled by means of an ice bath and held under reflux. It stops spontaneously after a few minutes.
On completion of the operation, a solution contain-ing 18 9 of 1-chloro-2-butene in 20 ml of dry ether is added in the absence of heat. The exothermic reaction is held under natural reflux which stops after about 15 minutes.
The cooled solution is washed with water containing ; an excess of hydrochloric acid in order to dissolve the magnesia formed. The ethereal solution is recovered by decan-tation and then dried. The ethylenic compound, namely 2-eicosene, is obtained in a quantitative yield. It is purified by distillation in va~uo at 160C/l mm Hg.
After the heads and tails have been removed, 7 9 of product are obtained, its composition and purity being readily verified by N.M.R.
i-.. ~,, , - , . , - ........................ - ......... .
- ~ .
lOS;~Z7~
A few epoxy alkanes corresponding to formula I and two comparison products, A-l and A-2, are shown in Table I
below, all these products having been prepared by Method A.
The 2,3-epoxy eicosane prepared by methods A and B is also shown in this table (Example 4).
It is recommended to use therapeutic compositions containing, in association with a physiologically acceptable excipient, a therapeutically effective quantity of at least one compound corresponding to formula I.
Any physiologically acceptabie liquid or solid vehi-cles may be used for preparing these therapeutic compositions containing the higher epoxy alkanes according to the invention.
; Solid preparations include, in particular, powders, tablets, granules, capsules, dragees and suppositories.
The solid vehicle which may be used contains one or more substances acting as diluent, perfume, solubilizer, lubricant, binder, surfactant or disintegration agent in the case of tablets. The solid vehicle may also contain one or more encapsulating substances. In powder form, the active compound is associated with a finely divided solid vehicle.
In tablets, the active compound is mixed in suitable pro-portions with a vehicle having the requisite binding proper-ties. The powders and tablets contain from 1 to 90% by weight of active ingredient. Suitable solid vehicles are, in par-ticular, magnesium carbonate, magnesium stearate, talcum saccharose, glucose, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxy methyl cellulose, -; low-melting waxes and cocoa butter.
,, .
Liquid preparations include solutions, suspensions and emulsions. In this case, the vehicle may be an aqueous solution of polyethylene glycol or polypropylene glycol on the .
: .
,, ,. . ~
i ~
lOS;~Z7~
one hand and oil, especially olive oil on the other hand.
The aqueous suspensions for oral administration are prepared by dispersing the finely divided active compound in water with a viscous substance, a natural or synthetic gum, a resin, etc., for example with gum arabic, an ion-exchange resin, methyl cellulose, carboxy methyl cellulose or any other well known suspending agent. The results of pharmacological tests carried out with the compounds according to the in-vention are summarized in the following.
The histological changes produced in the epithelium of adult rats were examined. It was found that the compounds according to the invention were capable of stimulating the function of the prostate gland in adult rats orally treated with very small doses over periods ranging from 15 days to 3 months. A significant improvement was then observed, for example with a dose of 0.5 mg per Kg of body weight per day in the case of the products of Examples 1 to 6.
Technique The epoxy alkane to be tested in an excipient, for example olive oil, was administered daily in the dose indi-cated for the period indicated to adult rats aged approxi-mately 9 months.
Control rats are only given the excipient.
in the test described, the animals were treated 6 days a week for 7 weeks. Each epoxy alkane was administered in solution in a volume of 0.1 ml/100 9 of body weight, i.e.
in a concentration of 0.5 9 of product per litre of oil.
- On completion of the test, the control animals and treated animals were killed, the ventral part of their - 30 prostate glands removed, fixed with alcohol and then histolog-ically examined.
lOS;~Z71 ~
The state of sections cut from the periphery of the prostate glands is noted in accordance with the following ~;
schedule:
Epithelium + 1 Enlargement of the peripheral epithelium of the central glands assuming a cubic appearance and occupying more than the outer half of the surface of the prostate gland.
Epithelium + 2 Enlargement of the epithelium, assuming a cylindri-cal appearance throughout.
Epithelium + 3 Epithelium identical throughout with that of theperipheral glands.
Epithelium + 4 Papillary hyperplasia of the epithelium with hyper-secretion (this "stage" was not observed in the tests con-ducted).
Table II below shows the results relating to the ventral prostates examined after killing of the controls and treated animals which had been given the epoxy alkanes of Examples 1 to 6 and comparison examples A-l and A-2 in the doses indicated.
Table II also shows the results of a statistical study carried out by the "chi 2" (x2) and the EPP index method.
The "chi 2" method enables the probability factor "p" to be deduced. The EPP index (examination of the periphery of the prostate gland) is defined as the ratio of the sum of all the -~
animals classed "epithelium 11'' bearing the coefficient 1, "epithelium 2+" bearing the coefficient 2 and "epithelium 3+"
bearing the coefficient 3 by the number of animals,...........
enables the statistical study to be confirmed. As indicated 105~271 in Table II, there is no activity when EPP is less than 1.80, whereas activity is found at the level of the prostate gland where EPP is greater than or equal to 1.80.
In conclusion, examination of the ventral part cut out from the periphery of the prostate glands shows that comparison products A-l and A-2, which respectively contain a Cg and C13 hydrocarbon radical, are inactive because they give a result similar to the control group. This absence of activity in products A-l and A-2 is confirmed by the statisti-cal study in relation to the controls in accordance with the "chi 2" method. In addition, in the series of epoxy alkanes corresponding to formula I, the activity of the level of the prostate glands begins to appear when the hydrocarbon radical -A contains at least 15 carbon atoms, as is the case with the compound of Example 1, in whose case a significant difference is noted in relation to the controls. The compounds of Examples 2 to 6 are highly active.
. .
It is apparent from the foregoing that the 1,2-epoxy alkanes of formula I are active when they contain in their molecule at least 18 carbon atoms, and that the 2,3-epoxy alkanes of formula I are active when they contain at least 19 carbon atoms ;n their molecule.
:. - g ' ' ~05~271 ,, ~ ~
O I O ~ O~ ~ O O U~ O
C~_ N 1~ ~ O ~ N
E ,_ ~ ~ . N N N N N
E o ~ o oo ~ ~ o m O L~ O
._ ~ ~~ I~ a~ o o o o ~- ~ ~ ~ ~ N N N N N
O ~
~ ~S
~ N 1~1 :
._ aJ ._ ._ O ~ ~
C~_ ~ :~ . r l~ O
~:n ~ ~ ,~ ~ ~ I
C-- O ~ ~ _ U~ ~, o) >, N (~0 O 00 N
~> ~ 3 3 r-- O ~ E ~.) O (_~ O
~ -- E
S ~ ~5 ~ ' ~ ' V~
O
o u~ I
._ V) ~5 ~r) N C~J O ~D O ~D N
1~ ~_ ~ ~ Ll~
cl r- ~ ~ <r~
,_ 18 >
~ ~00 ~ U~ l O
E
~_~ oI~ ~ o o ~ ,~
~ q_ 1~ 1-- 00 oo oo CO CO o~
L~ ~ ~
CS ~
I_ tl:l 01 ~ N ~ ~ _ ~ d' ~ C~
~ 0~ ~ O _ _ _ C~
N 1~ N 1~ N
~15 ~ 8 O d O O O 00 0 ~ O ~ O~O O d- O N
_ _ ~ CO N '~t ~~0 O 0~ d' N O a~ d' N 00 1 C ~ N _ ~ N ~) N ~t N d- t~) d- N
~- E
_ N ~ 00 0 N O N
E o _ _ _ N N N N N , I I I '-~ .- ~ ~ ~ ~
a) N tlS N ~ N a,l ~ 1) 1 U) N C- I ~.. ) I O I C ~ I O
1 0~ 1 0~ 1 0 V) I O U~ l O ~ l O ~ l O ~
I O ~~ I/ O I/ OI/ O I~ O I/ _ a~ I/ ~ ~ X C~ ~ t~ ) ~ U~_) ~) t_) Q 1~ ~ O I al I ~ I --I O I _I O I
o _ ~ o 1~ ~ o~ ~ ~ a) oo ~1 o _ ~ O~ I _ I _ I _ I _ I _ I _ I N
> C N X N X N X N X N X N X N X N X
~I) O I O I O I O I O I O I O I O I O
C~ 1~ C_) Q~.) Qt_~ Q C_~ QC_~ Q ~_) Q ~.7 Q ~_) Q
~r) N ~ N ~ N (~ N~) N~r I ^ I ^ I ^ I ^ I ^ I ^ I ^ I
r~ ~ ~ N C~ N ~ N
O
. Z ,_ Q _ N O N
E aJ , , N N N
0 ~1 ~ C~ _ N ~) ~ I L~) I ~ I
X O
- ' . . ,,:, ' ' -^ ^ ~VS;~Z'7~
V ~, _ ~ ~
o C ~ ~, cn o o o o ~) ~, ~ ~ c~ >, c ., ., _ ~
~ ~ c~ C c~-, a~ aJ a~ a~ aJ
E a~ s ~ > ~ ~ ~ ~ ~
a~ ~ Q ~ Q. ,-, , , , , ~ ^
o Eo E ~ ~ ~ ~ ~ ~ +
~ o~s o a cr ~cr ~ a tu ~ ~ ~ ~
E
., L~ U~ 1~ O O LO In O O
. ~ ~ ~ ~ c~ ~ o cn cs~
. c~ v . _~ ~ ~ N ~ ~ C~l ~ a~
L~ Q .
~ a~ E
o ~ x ~ ~ ~ ~ ~ ~ x ~
~ .-- ~ c-- ~ c~ c~ c-- c-- o 3 ~ ~ ~ a~ a~ ~ ~ a) . a~
~_ ~ --- ~ 3 u~ c~l 3 c~J ~ 3 ~ o 3 ~ o 3 ~ o ~ ~
~ v~ vl v~ ~ O O ~ O O ~ O O~ O O ~ O O O ^ E
o, a~ a~ ~ ~ ~ cJ ~ t ., ~ _ ~ C-- ~ O O ~ O O ~ O O~ O O1:~ 0 0 a5 N
E
c- I~ I~ u~ r~ ~ c~J ~ ~ ~5 ~
~ o o ~ I~ oo ~ m ~ o~ , O
E o N CO cn C~ N cn ,- _ o ~ . . . . . . . a~ ~
O N r~ 00 N C~J ~) 1~) C--aJ
_ _ +~ ~
+ S:L ~
a~ ~>
, +
n ILI
E
+ ~ t-c~ ~ .~>
E s 4-., , ., ~_ _ n cr a)oo1~1~ o oo ~ _ o o a~ ., ~ _ _ _ _ ~ ~
~ x c~ Q O
L~J _ ll ll ., +
., _ ~ In E
, ~ c~
c_c~l _ _, +~
.j , ~ .
'I CL
:` ~ .~ .
~ ~, ~
,, o ~s .) _ . ~ c--a~ 8 o o a~ o o o o o o v~ ~
E ~ N _ N N C`J C~
E-, - ~ ~
z ~ ~) v . Q ~ ~
.' .~ ~
_ +~
.
O _. ~ ^
Z ~- OC~l ~ V) V
O. - N C`J C~l N
a~ _ I I , , , .. ..
O ~ ~ ~ l C~
_ O C_ ~ ~ O ~+ 1~)~ `_ ~
~ _ 11 _ ,
Claims (10)
1. A composition useful in the treatment of secretory disorders of the prostate gland which comprises a compound of the formula:
wherein B represents H or CH3 and A represents a hydrocarbon radical containing from 15 to 20 carbon atoms, in admixture with a pharmaceutically acceptable carrier.
wherein B represents H or CH3 and A represents a hydrocarbon radical containing from 15 to 20 carbon atoms, in admixture with a pharmaceutically acceptable carrier.
2. The composition of Claim 1, wherein A is (CH2)15.
3. The composition of Claim 1, wherein A is (CH2)16.
4. The composition of Claim 1, wherein A is (CH2)17.
5. The composition of Claim 1, wherein A is (CH2)18.
6. The composition of Claim 1, wherein A is (CH2)19.
7. The composition of Claim 1, wherein A is (CH2)20.
8. The composition of Claim 1, wherein A is (CH2)16 and B is CH3.
9. The composition of Claim 1, wherein A is (CH2)18 and B is CH3.
10. The composition of Claim 1, wherein A is (CH2)20 and B is CH3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1068374A GB1453392A (en) | 1974-03-11 | 1974-03-11 | Epoxides and their therapeutic application |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1052271A true CA1052271A (en) | 1979-04-10 |
Family
ID=9972360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA221,651A Expired CA1052271A (en) | 1974-03-11 | 1975-03-10 | 1,2 - and 2,3 - epoxy alkanes |
Country Status (18)
Country | Link |
---|---|
JP (1) | JPS50135008A (en) |
AR (1) | AR206223A1 (en) |
AT (1) | AT342612B (en) |
BE (1) | BE826488A (en) |
CA (1) | CA1052271A (en) |
CH (1) | CH594652A5 (en) |
DE (2) | DE2559764C2 (en) |
DK (1) | DK80375A (en) |
ES (1) | ES435479A1 (en) |
FI (1) | FI60001C (en) |
FR (1) | FR2263761B1 (en) |
GB (1) | GB1453392A (en) |
IE (1) | IE40822B1 (en) |
IL (1) | IL46785A (en) |
NL (1) | NL7502845A (en) |
NO (1) | NO144151C (en) |
SE (1) | SE420724B (en) |
ZA (1) | ZA751489B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3633655A (en) * | 1970-09-23 | 1972-01-11 | United States Steel Corp | Construction for connecting and aligning sections of a guide-roll rack |
US4890714A (en) * | 1986-02-14 | 1990-01-02 | Brown H Gary | Conveying system |
-
1974
- 1974-03-11 GB GB1068374A patent/GB1453392A/en not_active Expired
-
1975
- 1975-01-01 AR AR257927A patent/AR206223A1/en active
- 1975-02-28 DK DK80375*#A patent/DK80375A/da not_active Application Discontinuation
- 1975-03-05 FR FR7506913A patent/FR2263761B1/fr not_active Expired
- 1975-03-05 DE DE2559764A patent/DE2559764C2/en not_active Expired
- 1975-03-05 DE DE2509503A patent/DE2509503C3/en not_active Expired
- 1975-03-10 IL IL46785A patent/IL46785A/en unknown
- 1975-03-10 ES ES435479A patent/ES435479A1/en not_active Expired
- 1975-03-10 NO NO750785A patent/NO144151C/en unknown
- 1975-03-10 CA CA221,651A patent/CA1052271A/en not_active Expired
- 1975-03-10 SE SE7502641A patent/SE420724B/en unknown
- 1975-03-10 BE BE154179A patent/BE826488A/en not_active IP Right Cessation
- 1975-03-11 JP JP50029975A patent/JPS50135008A/ja active Pending
- 1975-03-11 FI FI750692A patent/FI60001C/en not_active IP Right Cessation
- 1975-03-11 CH CH308675A patent/CH594652A5/xx not_active IP Right Cessation
- 1975-03-11 NL NL7502845A patent/NL7502845A/en not_active Application Discontinuation
- 1975-03-11 ZA ZA00751489A patent/ZA751489B/en unknown
- 1975-03-11 AT AT185975A patent/AT342612B/en not_active IP Right Cessation
- 1975-03-11 IE IE525/75A patent/IE40822B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE2509503B2 (en) | 1980-04-24 |
FI60001B (en) | 1981-07-31 |
DE2559764C2 (en) | 1983-05-05 |
NO144151B (en) | 1981-03-23 |
ES435479A1 (en) | 1977-01-01 |
FR2263761B1 (en) | 1980-02-22 |
CH594652A5 (en) | 1978-01-13 |
ZA751489B (en) | 1976-02-25 |
ATA185975A (en) | 1977-08-15 |
FI60001C (en) | 1981-11-10 |
FI750692A (en) | 1975-09-12 |
IL46785A (en) | 1978-06-15 |
BE826488A (en) | 1975-06-30 |
IE40822L (en) | 1975-09-11 |
FR2263761A1 (en) | 1975-10-10 |
NO750785L (en) | 1975-09-12 |
NO144151C (en) | 1981-07-01 |
SE420724B (en) | 1981-10-26 |
DE2509503A1 (en) | 1975-09-18 |
AU7897575A (en) | 1976-09-16 |
IE40822B1 (en) | 1979-08-29 |
JPS50135008A (en) | 1975-10-25 |
SE7502641L (en) | 1975-09-12 |
NL7502845A (en) | 1975-09-15 |
DE2509503C3 (en) | 1980-12-18 |
IL46785A0 (en) | 1975-05-22 |
GB1453392A (en) | 1976-10-20 |
DK80375A (en) | 1975-09-12 |
AR206223A1 (en) | 1976-07-07 |
AT342612B (en) | 1978-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Van Duuren et al. | Carcinogenicity of epoxides, lactones, and peroxy compounds. VI. Structure and carcinogenic activity | |
EP0036663B1 (en) | Oxiranebutanoic acid derivatives, their preparation and use, and medicaments containing them | |
US4186211A (en) | Higher alkanol compositions and the use thereof in treatment of prostate disorders | |
EP0019377A1 (en) | 1-Hydrocarbyloxyphenyl-1,2-diphenylalkene derivatives, their manufacture and a pharmaceutical composition containing them | |
EP0339549A3 (en) | Tyr-peptide analogs | |
CA1052271A (en) | 1,2 - and 2,3 - epoxy alkanes | |
FR2409259A1 (en) | PEPTIDES, ACID ADDITIONAL SALTS THEREOF AND PROCESS FOR THEIR PREPARATION | |
FR2518091A1 (en) | 23-DEHYDRO-25-HYDROXYVITAMINE D3, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
Dann et al. | A rapid and convenient technique for converting ketones into their ethylenedioxy-or trimethylenedioxy-derivatives, and for making acetonides | |
US4540709A (en) | Method for treatment of diseases mediated by PAF using 5-allyl-2-(3,4-Dimethoxyphenyl)-3a,α-methoxy-3-methyl-2,3,3a,6-tetrahydro-6-oxobenzofuran | |
US4113875A (en) | Compositions for the treatment of disorders of the prostate gland | |
CH678853A5 (en) | ||
DE2145125A1 (en) | Prostanoic acid derivatives and their production | |
CA1079306A (en) | Sulphur containing hydroxy aliphatic compounds | |
US3899526A (en) | Extract containing prostaglandins | |
DE2603172A1 (en) | PROSTAGLAND INANTAGONISTS, THE METHOD OF MANUFACTURING THEM AND THE MEDICINAL PRODUCTS CONTAINING THEM | |
DE2709347A1 (en) | ERYTHRO-15,16-DIOXYPROSTIC ACIDS AND ESTERS AND THE PROCESS FOR THEIR PRODUCTION | |
EP0104631A2 (en) | Clavulone derivatives, process for preparing the same, and use of said compounds | |
US2944079A (en) | Nn-di-chloroethylaminobutyrates and preparation thereof | |
KR850008619A (en) | Process for preparing nifedipine composition | |
US4647676A (en) | Process for the isolation of 2,2-dimethyl-7-hydroxy-coumaran | |
JPS5545649A (en) | Novel nootkatone and vetivone derivative, their novel intermediate, their preparation and use | |
DE3335389A1 (en) | 15-CYCLOALIPHATIC DERIVATIVES OF 13,14-DIDEHYDROCARBOPROSTACYCLINES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL OR VETERINARY AGENTS THAT CONTAIN THEM | |
US3900513A (en) | Extract containing prostaglandins | |
DE1643159A1 (en) | Process for the preparation of prostaglandin derivatives and compounds with prostaglandin-like activity |